latest news releases from the newsroom
Lundin Petroleum AB
LUNDIN NORWAY SIGNS RIG CONTRACT FOR UNIT TRANSOCEAN WINNER
The duration of the contract is in excess of three years and the rig
utilization to be shared equally between the three operators Lundin Petroleum,
Marathon and Talisman as dictated by a separate rig sharing agreement. The
contract will commence in August 2009 and the contract value is approximately
$500 million USD. This rig contract will allow Lundin Petroleum to further
pursue a proactive exploration, appraisal and development strategy on the
Norwegian Continental Shelf.
Foundry Networks, Inc.
Foundry Networks to Share Converged Communication Strategies At VoiceCon Orlando 2008
SANTA CLARA, Calif. and ORLANDO, Fla., March 13, 2008 (PRIME NEWSWIRE) -- Foundry Networks(r), Inc. (Nasdaq:FDRY), a performance and total solutions leader for end-to-end switching and routing, today announced that it will be participating and exhibiting at VoiceCon Orlando 2008, March 17 to 20, in Orlando, Fla. Foundry's(tm) Franchesca Walker will participate in a Leading EDGE-ucation session and panel discussion on converged communication strategies at the Gaylord Palms Resort and Convention Center. In addition to these speaking engagements, Foundry will also be exhibiting networking solutions for unified and converged communications at booth 1023 in the exhibit hall.
Organa Technologies Group, Inc.
Organa Technologies Group, Inc. ('Organa') Announces 1-For-4 Forward Split
MELBOURNE, Fla., March 13, 2008 (PRIME NEWSWIRE) -- Organa Technologies Group, Inc. (Other OTC:OGNT) announced today a stock symbol change (from OGTG.PK to OGNT.PK) as well as a 1-for-4 forward split of its common stock. The Company announced the deadline for all shareholders to convert their Organa stock by September 12, 2008. Shareholders wishing to do so should send their stock certificates to Organa Technologies Group, Inc. Attn: Stock Administrator, 2910 Bush Drive, Melbourne, FL 32935 or contact Gina L. Bennett at the Company, 321-421-6663.
Ceragenix Completes Patient Visit Phase of Clinical Trial Study to Compare Efficacy of EpiCeram(R) to Elidel(R)
DENVER--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP) (the "Company"), a biopharmaceutical and medical device company focused on infectious disease and dermatology, today announced that it had completed the patient visit phase of its previously announced clinical trial to assess the safety and efficacy of EpiCeram® relative to Elidel® in treating the symptoms associated with eczema such as itch and redness as measured by the EASI scoring system. Elidel is the leading immunosuppressant topical therapy for the short-term treatment of atopic dermatitis. The randomized, double blind study consisted of children between the ages of 2 and 18 years and was conducted at two academic sites. For a four-week period, half of the subjects received treatment with EpiCeram® and the other half received treatment with Elidel®. While the study had a goal of enrolling at least 50 patients, study enrollment was terminated at 36 patients as the rate of enrollment at the two sites did not anticipate timely completion of the full cohort of patients. The study results are currently undergoing statistical analysis and the Company expects to receive the final study report during the second quarter of 2008 at which time it will announce the results.
Izard Nobel LLP
Schatz Nobel Izard P.C. Announces Class Action Lawsuit Against Force Protection, Inc.
HARTFORD, Conn., March 13, 2008 (PRIME NEWSWIRE) -- The law firm of Schatz Nobel Izard P.C., which has significant experience representing investors in prosecuting claims of securities fraud, announces that a lawsuit seeking class action status has been filed in the United States District Court for the District of South Carolina on behalf of all persons who purchased the common stock of Force Protection, Inc. ("Force Protection" or the "Company") (Nasdaq:FRPT) between August 14, 2006 and February 29, 2008, inclusive (the "Class Period").